Netupitant

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- On November 5, the 7th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center in Shanghai. As a seven-time attendee of the CIIE, Fosun showcased the latest achievements in innovation and global operations at its Fosun Pharma booth in Hall 7.1, featuring cutting-edge medical devices and innovative pharmaceuticals that made their debut in China. Guo Guangchang, Chairman of Fosun International, remarked, "Over the past seven years, CIIE has improved every year, becoming a window for China to build a new development framework, a platform for high-level openness, and an international public product for global sharing. Fosun has been a participant, witness, and beneficiary of the CIIE. Leveraging the CIIE platform, our long-term innovations have continually been put into practice, transforming many 'exhibits' into 'products', and converting many overseas partners from 'exhibitors' into 'investors'. This year, we continue to showcase our latest achievements in integrated innovation in the medical device and health sector, including several 'world's firsts' and 'China's firsts'. We firmly believe that China remains a significant opportunity for global development. Together with more overseas companies and global partners, we will promote more cutting-edge innovations to take root in China, moving forward and achieving mutual success on the grand stage of the CIIE." Stars of CIIE Taking Root, Transforming Ion from "Exhibit" to "Product" Healthcare is one of Fosun's main businesses. With CIIE's "spillover effect," several star products from Fosun, supported by the CIIE "accelerator" effect, have successfully entered the market to serve Chinese patients, transforming from "exhibits" into "products". This year, following the popular da Vinci Surgical System, the Ion Robotic Bronchoscopy made its CIIE debut after receiving domestic approval. Since its first appearance at the CIIE in 2019, Ion caught the attention of visitors. By the end of 2022, Ion entered the National Medical Products Administration's 'Green Channel' for innovative products and gained approval in March 2024, with the first commercial application completed in September. Lung cancer is considered the leading cause of cancer deaths, with 1.06 million new cases in China in 2022. The five-year survival rate is only 19.7%, and bronchoscopy is a key diagnostic tool for early lung cancer detection. The Ion bronchoscopy navigation control system offers innovative features for precise, convenient clinical diagnosis, providing new options for patients. By the third quarter of this year, 736 Ion systems had been installed globally, with over 150,000 Ion procedures performed. Outside the CIIE exhibition hall, Fosun is accelerating the localization of advanced medical devices. In June this year, Intuitive Fosun's headquarter industrial base was launched in Shanghai, marking Intuitive's largest R&D, production, and training center in the Asia-Pacific region. At this base, in addition to the Ion shape-sensing bronchoscopy control system, advanced products and core components, including the da Vinci surgical robot, are gradually achieving "Made in China, joint R&D, and global sales." Accelerating Integrated Innovation to Lead in Neurological Disease Treatment Transformation Fosun has long committed to investing in cutting-edge areas of healthcare, fostering a continuous stream of breakthrough "solid achievements" through an open innovation ecosystem involving independent R&D, collaborative development, licensing, and industry investment. These innovations are continually transformed into new drivers of growth. At this year's CIIE, Fosun introduced several latest products that are leading industry transformation. In the field of neurological disease treatment, especially for conditions like essential tremor and Parkinson's disease, patients have long faced challenges with unmet clinical needs. Traditional drug and surgical treatments often have limitations, but advancements in non-invasive treatment technologies have brought new hope to these patients. Fosun has actively responded to this unmet clinical need. At this year's CIIE, the new V2 model of the CNS (Central Nervous System) innovative treatment technology, the V2 model of "Exablate Neuro FUS system" made its debut in China, generating high expectations within the industry. This new model has already received CE certification in Europe and FDA approval in the United States and submitted a registration application to China's National Medical Products Administration in 2024. The V2 model's innovation lies in providing a non-invasive surgical solution for clinically drug-resistant essential tremor and tremor-dominant Parkinson's disease, while also being compatible with a broader range of MRI models, further enhancing the accessibility of this technology. Last year, Fosun, in partnership with Insightec, showcased the "Exablate Neuro" at CIIE, drawing much attention and continuous interest in collaboration. Leveraging the CIIE's "spillover effect", Fosun Pharma and Insightec established a joint venture, Fosun-Insightec, in February this year. The venture is focused on the marketing and developing clinical efforts of Exablate Neuro FUS system in improving the lives of patient living with essential tremor and Parkinson's disease, working to help them regain their quality life and wellbeing. Focusing on innovating to meet real customer needs is a core methodology for Fosun. Data shows that Fosun has made long-term investments in technological innovation, with an investment of RMB 3.5 billion in the first half of this year. Connecting Globally to Enhance Accessibility of Innovative Drugs, Benefiting more Patients Leveraging the CIIE's openness, Fosun also presented innovative products focused on solid tumors, hematological tumors, and immune-inflammatory conditions. Fosun's seven-year journey at CIIE has facilitated the introductions of global products and enabled the export of local innovations to benefit more patients worldwide. In 2017, Fosun introduced China's first CAR-T cell therapy product, Yi Kai Da (ejilunsai injection). Since then, by continuously participating in the CIIE, Fosun has enabled the public to gain an in-depth understanding of this advanced therapy. At this year's CIIE, Fosun highlighted Yi Kai Da's latest developments in the "accessibility and treatability" in lymphoma treatment. Yi Kai Da is now included in over 110 urban customized commercial health insurances and more than 80 commercial insurances, created a new path of payment mode for patients; and over 170 high-standard treatment centers across 28 regions in China providing treatments for over 900 lymphoma patients, achieving revolutionary innovative breakthroughs for cancer care. As a global company rooted in China, Fosun has an extensive industrial presence in over 35 countries and regions worldwide, with robust global R&D capabilities and impressive progress. This year, Fosun also showcased several innovative products, including the world's first and only dual-channel fixed-dose combination oral formulation, Akynzeo® oral (Netupitant and Palonosetron hydrochloride), which blocks both NK-1 and 5-HT3 receptors; the immunoglobulin Thymoglobulin® for improving transplant patient outcomes; the world's first oral targeted medication for psoriasis, Otezla® (apremilast tablets); a new third-generation COMT inhibitor Ongentys® (Opicapone) for managing symptom fluctuations in adult Parkinson's disease patients; and Parsabiv® (Etelcalcetide Hydrochloride Injection), the only peptide-based calcimimetic for treating secondary hyperparathyroidism in adult dialysis patients with chronic kidney disease. Guo Guangchang concluded, "Participating in CIIE has been a top priority for Fosun for seven consecutive years. We have witnessed CIIE become a crucial platform for global companies to share in China's development opportunities and deepened our global partnerships through this platform. We believe the CIIE stage will continue to expand, and Fosun's journey of innovation and globalization will grow broader." SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

On June 12, Swiss pharmaceutical company Helsinn Healthcare announced the renewal of its distribution and licensing agreement with Chugai Pharma Europe, the European subsidiary of Japanese pharmaceutical company Chugai, to promote AKYNZEO® (a combination drug containing netupitant and palonosetron) in the UK and Ireland. It is reported that AKYNZEO® was first approved in the United States by the FDA in 2014 as a medication used to treat chemotherapy-induced nausea and vomiting. It consists of two active ingredients: netupitant and palonosetron. Netupitant is a neurokinin NK1 receptor antagonist that selectively blocks the activation of NK1 receptors, reducing delayed nausea and vomiting caused by chemotherapy. Palonosetron is a serotonin 5-HT3 receptor antagonist that blocks the activation of 5-HT3 receptors, reducing acute nausea and vomiting induced by chemotherapy. The indication for AKYNZEO® primarily involves the prevention of acute and delayed nausea and vomiting associated with highly or moderately emetogenic chemotherapy in adults. It is typically used in conjunction with dexamethasone to enhance the preventive effect. The pharmaceutical forms of the drug include capsules and injections, with each capsule containing 300 mg of netupitant and 0.5 mg of palonosetron. The recommended dosage and administration of AKYNZEO® is to take one capsule orally at least one hour before the start of chemotherapy, and only once per chemotherapy cycle. However, use should be avoided or administered with caution under physician guidance in patients with severe hepatic impairment, severe renal impairment or end-stage renal disease, and pregnant or breastfeeding women. Common adverse reactions of AKYNZEO® include headache, constipation, fatigue, and stomach discomfort. AKYNZEO® is an effective supportive medication for chemotherapy, significantly improving the quality of life during chemotherapy by alleviating symptoms like nausea and vomiting. When using this medication, patients should follow the guidance and recommendations of their physician to ensure safe and effective use. Nausea and vomiting are common physical discomfort symptoms that can be caused by a variety of reasons. Nausea is a sensation of unease in the stomach that may be accompanied by an urge to vomit, while vomiting involves the forceful expulsion of stomach contents through the mouth. Nausea and vomiting can be symptoms of many different health conditions, including early pregnancy, concussion, cancer chemotherapy, and gastroenteritis. Both adults and children can experience these symptoms, and methods to alleviate nausea vary from person to person. However, some common home remedies include drinking clear liquids or chilled beverages, eating bland foods such as saltine crackers or white bread, avoiding greasy or sweet foods, eating slowly, having smaller, more frequent meals, not mixing hot and cold foods, sipping beverages slowly, avoiding activity after eating, not brushing teeth immediately after meals, and choosing foods that are tolerable to ensure a balanced diet. Chemotherapy-induced nausea and vomiting (CINV) are common side effects during chemotherapy processes, significantly affecting the quality of life for cancer patients undergoing treatment and are among the most feared adverse events associated with chemotherapy. CINV not only impacts the patient's day-to-day life but can also cause psychological stress, sometimes even leading patients to delay or refuse necessary chemotherapy treatments. The occurrence of CINV (Chemotherapy-induced Nausea and Vomiting) presents two peak periods: an acute phase within 1-2 hours post-chemotherapy, known as Acute CINV, and another peak occurring between 48-72 hours after chemotherapy, which can last several days, known as Delayed CINV. The incidence of Delayed CINV is approximately twice that of Acute CINV. However, during the delayed phase of chemotherapy, patients often no longer have direct contact with the oncology medical team, posing challenges for clinical management. Moreover, most antiemetic treatments are more effective against Acute CINV than Delayed CINV. The pathogenesis of CINV involves both the central and peripheral nervous systems. Chemotherapy drugs lead to the release of various neurotransmitters in the gastrointestinal tract, cerebral cortex, thalamus, vestibular areas, and the area postrema, which includes dopamine, endorphins, serotonin, and neurokinin, with substance P as a receptor ligand. 5-HT3 receptor antagonists (5-HT3 RAs) have shown effectiveness in controlling acute CINV but have limited efficacy in Delayed CINV. In recent years, the introduction of neurokinin-1 (NK-1) receptor antagonists has represented a relevant advancement in preventing CINV associated with highly and moderately emetogenic chemotherapy, particularly in the delayed phase. Anti-emetic drugs targeting the NK1R receptor include:  ·Aprepitant, the first NK1R receptor antagonist approved globally, was developed and clinically indicated by Merck. Aprepitant can be used in combination with other anti-emetics to prevent acute and delayed nausea and vomiting associated with the initial and repeat courses of high emetogenic cancer chemotherapy.  ·Fosaprepitant (L-758,298, MK-0517) is the second globally marketed NK1R receptor antagonist developed by Merck, with the initial indication still being chemotherapy-induced nausea and vomiting.  ·Rolapitant (SCH-619734) is a highly selective NK1R receptor antagonist originally developed by Schering Plough Corporation.  ·The mentioned combination of Netupitant/Palonosetron consists of the NK1R receptor antagonist Netupitant and the 5-HT3R antagonist Palonosetron. Developed by Helsinn Healthcare of Switzerland, it is indicated primarily for nausea and vomiting caused by chemotherapy. In the targeted antiemetic drugs treating GPCR-related targets, besides NK1R receptors, agents that interact with receptors like D2R, CB, and 5-HT, also represent significant market opportunities. As a relatively niche therapeutic avenue, currently, there are few GPCR-targeting antiemetic projects with marketing applications and clinical investigations. Prominent drugs include HR-20013, dronabinol hemisuccinate, and relamorelin. As reported, in December 2023, the CDE official site publicized that Suncadia Medicine, a subsidiary of Hengrui Pharmaceuticals, submitted an application for market approval of the injectable HR20013, which was accepted. HR20013 is a combination of NK-1RA and 5-HT3RA intended to be developed for the prevention of post-chemotherapy nausea and vomiting, with HR-20013 being an active component. Once administered, HRS5580 is rapidly converted into Rolapitant through non-CYP450 enzyme systems like thiol methyltransferase. Dronabinol is another product developed by INSYS Therapeutics as a non-selective CB receptor agonist. It is also used to treat nausea and vomiting induced by chemotherapy, especially when other antiemetic drugs have not been effective. Dronabinol functions by activating cannabinoid receptors in the brain, helping to reduce the sensation of nausea and decreasing the frequency of vomiting. It is typically available in the form of oral capsules, taken before chemotherapy to prevent nausea and vomiting. Although Dronabinol can effectively alleviate nausea and vomiting caused by chemotherapy, it may also have some side effects, including dizziness, dry mouth, fatigue, and confusion. Before using Dronabinol or any other medication, patients should discuss the potential benefits and risks with their healthcare professionals. How to obtain the latest research advancements in the field of biopharmaceuticals? In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!